Remdesivir Limited use to sickest COVID-19 patients

▴ Remdesivir Limited use to sickest COVID-19 patients
Some hospitals said they are still buying the Gilead Sciences medicine to build inventory in case the pandemic accelerates over the winter

U.S. hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as the need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed on Friday.

Some hospitals said they are still buying the Gilead Sciences medicine to build inventory in case the pandemic accelerates over the winter. But they said current supplies are adequate, in part because they are limiting use to severely ill patients.

The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases.

The slowdown suggests that a shortage of the drug is over and threatens Gilead's efforts to expand the use of remdesivir, which it sells under the brand name Veklury in some countries.

An HHS spokesperson confirmed on Friday that between July 6 and September 8, state and territory public health systems accepted about 72% of the remdesivir they were offered. Hospitals in turn purchased only about two-thirds of what states and territories accepted, as previously detailed to Reuters by Michael Ganio, senior director of pharmacy practice and quality at the American Society of Health-System Pharmacists.

Gilead did not respond to a request for comment.

A surplus of remdesivir - which costs $3,120 for a 6-vial intravenous course - marks a turnaround from earlier in the pandemic, when supplies of the drug had fallen short of demand in some regions.

The government-led distribution of remdesivir will expire at the end of September. Hospitals said they have little information on availability after that.

Remdesivir was first authorized by the FDA in May for emergency use in COVID-19 patients hospitalized and on oxygen support after data showed it helped shorten hospital recovery time.

'Not Impressed'

The agency last month expanded use to hospitalized patients who do not require oxygen support, based on data published in the JAMA medical journal showing that the drug provided a modest benefit for those patients.

The newer data has left many experts unconvinced.

"I am not impressed with the study," said Dr. Adarsh Bhimraj, an infectious disease specialist at the Cleveland Clinic. He said he remains "skeptical" about using remdesivir in patients with moderate COVID-19, especially given the price.

Dr. Rajesh Gandhi, an infectious disease physician at Massachusetts General Hospital in Boston, said his center has stayed focused on using remdesivir for the narrower population of seriously ill patients who need supplemental oxygen.

"No one wants to be in a position of making treatment decisions based on drug availability," he said.

Houston Methodist Hospital is holding off on broader use of remdesivir, and instead is stockpiling it in case of the pandemic flares up in winter - typically the peak season for respiratory illness.

"At this point, we are buying far more than we are using because we are unsure about what will happen at the end of September," said Katherine Perez, infectious disease pharmacist at Houston Methodist.

There is no evidence that COVID-19 patients admitted to the hospital for a day or two due to an underlying health issue, like diabetes or high blood pressure, would benefit from the drug, she added.

Mark Sullivan, associate chief pharmacy officer at Nashville's Vanderbilt University Hospitals & Clinics, said his institution also did not expand remdesivir use based on the newer JAMA data.

"We have kept our treatment protocol the same," he said.

Tags : #COVID-19 #USA #Remdesiver #Gilead

About the Author


Dr. Naila Syed

A well presented, self-motivated, and confident writer. Passionate about educating the masses on medical and nonmedical ways to promote health and lifestyle through my mighty pen.You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-

Trending Now

China ropes in more countries for its COVID-19 vaccine trialsSeptember 29, 2020
Antarctica is still free of Covid-19. Can it stay that way?September 29, 2020
Over 200 travellers from India barred from Dubai flight over invalid Covid-19 testsSeptember 29, 2020
Netherland focuses on more stricker rule to comabt COVID-19 September 29, 2020
WHO aims to provide 120 Million rapid Coronavirus tests for poorer statesSeptember 29, 2020
UN chief on 1 Million COVID-19 deathsSeptember 29, 2020
Bahrain reports 585 Covid-19 cases, 777 recoveriesSeptember 28, 2020
Bringing hepatitis C testing and treatment to underserved communities in MadridSeptember 28, 2020
Polish doctor recovers from severe COVID-19 through rehabilitationSeptember 28, 2020
WHO supports rehabilitation of COVID-19 and other patients in UkraineSeptember 28, 2020
WHO work with migrant camps in Greece September 28, 2020
US employers being sued for COVID-19 infection spread September 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Highly effective antibodies identified, may lead to passive COVID-19 vaccineSeptember 26, 2020
Europe has a lot of work to do to prevent COVID-19 transmission :WHOSeptember 26, 2020
Two million Coronavirus deaths : WHO September 26, 2020
Johnson & Johnson COVID-19 vaccine produces strong results September 26, 2020
New York to permanently switch to outdoor dining amid pandemicSeptember 26, 2020
WHO gave blessing for Coronavirus vaccine emergency use programme: ChinaSeptember 26, 2020
US surpasses 7 Million Coronavirus casesSeptember 26, 2020